CEO Thomas Burns was paid $12,034,087 in fiscal year 2025, ↑ up 33.3% from fiscal year 2024, the 52nd percentile of its disclosed peer group (SEC filing 0001193125-26-157829 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$12,034,087 ↑ Thomas Burns total, FY2025 | 52nd CEO pay percentile vs peers | 67.4:1 CEO-to-median pay ratio | 91.77% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
GKOS's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Burns | $850,000 | $0 | $7,649,947 | $3,527,497 | $0 | $0 | $6,643 | $12,034,087 |
| Chairman of the Board & Chief Executive Officer | ||||||||
| Joseph Gilliam | 584,850 | 0 | 6,500,013 | 0 | 689,006 | 0 | 11,750 | 7,785,619 |
| President and Chief Operating Officer | ||||||||
| Tomas Navratil | 499,400 | 0 | 2,399,930 | 0 | 504,290 | 0 | 11,750 | 3,415,370 |
| Chief Development Officer | ||||||||
| Alex Thurman | 486,200 | 0 | 0 | 2,435,481 | 0 | 0 | 15,750 | 2,937,431 |
| Senior Vice President & Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Burns | $12,034,087 | $9,030,345 | $8,654,684 | ↑ +3,003,742 |
| Joseph Gilliam | 7,785,619 | 4,163,652 | 4,179,081 | ↑ +3,621,967 |
| Tomas Navratil | 3,415,370 | 2,780,975 | 2,566,156 | ↑ +634,395 |
| Alex Thurman | 2,937,431 | 2,457,375 | 2,359,969 | ↑ +480,056 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read GLAUKOS Corp's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper GKOS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the GLAUKOS Corp Peer Teardown Report
$12,034,087 Thomas Burns total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 7, 2026 · Source: 0001193125-26-157829 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for GKOS
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order GKOS
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses GKOS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GKOS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the GLAUKOS Corp Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Alex Thurman | CFO | $2,937,431 |
| Joseph Gilliam | President | $7,785,619 |
| Thomas Burns | CEO | $12,034,087 |
| Tomas Navratil | Chief Development Officer | $3,415,370 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Aimee S. Weisner | Independent Director | $428,989 |
| David F. Hoffmeister | Independent Director | $443,359 |
| Denice M. Torres | Independent Director | $428,989 |
| Gilbert H. Kliman, M.D | Independent Director | $428,989 |
| Leana S. Wen, M.D | Independent Director | $428,989 |
| Marc A. Stapley | Independent Director | $440,515 |
| Mark J. Foley | Lead Independent Director | $489,311 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-04-30 | D | 10,000 | $39 | $386,800 | Derivative, Class A Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-04-30 | D | 10,000 | 140 | 1,400,000 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-04-30 | A | 10,000 | 39 | 386,800 | Common | Form 4 ↗ |
| Leana Wen | Director | 2026-05-01 | D | 1,700 | 143 | 243,695 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-05-01 | D | 19,573 | 144 | 2,809,508 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-11 | D | 5,000 | 25 | 123,450 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-11 | D | 5,000 | 135 | 675,000 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-11 | A | 5,000 | 25 | 123,450 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-14 | D | 5,000 | 25 | 123,450 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-14 | A | 5,000 | 25 | 123,450 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-14 | D | 5,000 | 141 | 703,800 | Common | Form 4 ↗ |
| David F. Hoffmeister | Director | 2026-05-26 | D | 15,000 | 25 | 370,350 | Derivative, Class A Common | Form 4 ↗ |
| David F. Hoffmeister | Director | 2026-05-26 | A | 15,000 | 25 | 370,350 | Common | Form 4 ↗ |
| Marc A. Stapley | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| David F. Hoffmeister | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Foley | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Foley | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| Denice M. Torres | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Denice M. Torres | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| Aimee S. Weisner | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aimee S. Weisner | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| Leana Wen | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Denice M. Torres | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David F. Hoffmeister | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aimee S. Weisner | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marc A. Stapley | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leana Wen | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark J. Foley | Director | 2026-05-28 | A | 2,987 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leana Wen | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| David F. Hoffmeister | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| Marc A. Stapley | Director | 2026-05-28 | A | 1,878 | 0 | 0 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-06-16 | D | 1,537 | 131 | 200,855 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-06-25 | D | 483 | 143 | 68,861 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-06-25 | D | 1,056 | 143 | 150,554 | Common | Form 4 ↗ |
| Thomas William Burns | Director | 2026-06-25 | D | 4,059 | 143 | 578,692 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-07-01 | D | 716 | 139 | 99,567 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 10,000 | 39 | 386,800 | Derivative, Class A Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 10,000 | 150 | 1,500,000 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-06 | A | 10,000 | 39 | 386,800 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-09 | A | 10,000 | 39 | 386,800 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-09 | D | 10,000 | 155 | 1,550,000 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-16 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-16 | D | 10,000 | 160 | 1,600,000 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-07-16 | A | 10,000 | 39 | 386,800 | Common | Form 4 ↗ |
| Leana Wen | Director | 2026-07-31 | D | 525 | 168 | 88,006 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-08-07 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-08-07 | A | 20,000 | 34 | 676,200 | Common | Form 4 ↗ |
| Alex Thurman | SVP & CHIEF FINANCIAL OFFICER | 2026-08-07 | D | 20,000 | 180 | 3,602,600 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 27,963 | 179 | 5,002,301 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | A | 10,000 | 48 | 484,600 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | A | 20,000 | 55 | 1,103,600 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | A | 20,000 | 55 | 1,103,600 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | A | 10,000 | 48 | 484,600 | Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Gilliam | PRESIDENT & COO | 2026-08-11 | D | 32,037 | 180 | 5,782,358 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-08-19 | D | 2,500 | 190 | 475,000 | Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-08-19 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gilbert H. Kliman | Director | 2026-08-19 | A | 2,500 | 26 | 64,425 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-08-28 | D | 6,091 | 181 | 1,103,628 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-08-28 | D | 10 | 183 | 1,825 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-08-28 | D | 7,643 | 180 | 1,377,651 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 234 | 171 | 40,002 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 120 | 168 | 20,206 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 460 | 167 | 76,967 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 4 | 172 | 688 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 191 | 166 | 31,744 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 103 | 163 | 16,810 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-16 | D | 345 | 165 | 56,787 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-25 | D | 1,083 | 155 | 167,735 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-25 | D | 229 | 154 | 35,321 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-25 | D | 136 | 153 | 20,769 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-09-25 | D | 167 | 152 | 25,334 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-10-05 | D | 312 | 166 | 51,667 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-10-05 | D | 327 | 165 | 53,883 | Common | Form 4 ↗ |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 2026-10-05 | D | 888 | 164 | 145,570 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joseph Gilliam | OTHER | — | — | — | — | — | $6,500,013 |
| Thomas Burns | OTHER | — | — | — | — | — | 7,649,947 |
| Tomas Navratil | OTHER | — | — | — | — | — | 2,399,930 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joseph Gilliam | PSU | 54,930 | — | $6,202,146 |
| Tomas Navratil | PSU | 24,844 | — | 2,805,136 |
| Joseph Gilliam | PSU | 36,232 | — | 4,090,955 |
| Thomas Burns | Option | 21,016 | 85.78 | — |
| Joseph Gilliam | PSU | 37,889 | — | 4,277,991 |
| Thomas Burns | PSU | 15,417 | — | 1,740,733 |
| Alex Thurman | Option | 19,849 | 96.6 | — |
| Thomas Burns | RSU | 15,957 | — | 1,801,705 |
| Tomas Navratil | RSU | 5,135 | — | 579,793 |
| Tomas Navratil | RSU | 8,307 | — | 937,943 |
| Thomas Burns | PSU | 79,192 | — | 8,941,569 |
| Joseph Gilliam | RSU | 43,587 | — | 4,508,417 |
| Thomas Burns | PSU | 92,194 | — | 10,409,568 |
| Thomas Burns | PSU | 13,584 | — | 1,533,769 |
| Joseph Gilliam | RSU | 10,318 | — | 1,165,005 |
| Joseph Gilliam | RSU | 6,558 | — | 740,464 |
| Thomas Burns | Option | 2,631 | 55.18 | — |
| Tomas Navratil | RSU | 27,668 | — | 2,965,844 |
| Joseph Gilliam | RSU | 18,116 | — | 2,045,478 |
| Alex Thurman | RSU | 4,531 | — | 511,595 |
| Tomas Navratil | RSU | 12,422 | — | 1,402,568 |
| Joseph Gilliam | Option | 8,637 | 85.78 | — |
| Alex Thurman | RSU | 17,460 | — | 1,776,504 |
| Tomas Navratil | RSU | 11,694 | — | 1,320,370 |
| Thomas Burns | RSU | 39,596 | — | 4,470,784 |
| Joseph Gilliam | Option | 11,486 | 48.46 | — |
| Thomas Burns | RSU | 71,287 | — | 6,891,404 |
| Tomas Navratil | PSU | 23,997 | — | 2,709,445 |
| Joseph Gilliam | PSU | 3,886 | — | 438,768 |
| Thomas Burns | PSU | 24,290 | — | 2,742,584 |
| Tomas Navratil | PSU | 23,386 | — | 2,640,513 |
| Alex Thurman | PSU | 21,470 | — | 2,424,121 |
| Joseph Gilliam | RSU | 13,592 | — | 1,534,673 |
| Tomas Navratil | PSU | 1,948 | — | 219,949 |
| Joseph Gilliam | RSU | 9,062 | — | 1,023,190 |
| Tomas Navratil | PSU | 6,677 | — | 753,900 |
| Alex Thurman | RSU | 5,503 | — | 621,344 |
| Thomas Burns | RSU | 5,211 | — | 588,374 |
| Alex Thurman | RSU | 3,717 | — | 419,686 |
| Thomas Burns | Option | 13,548 | 48.46 | — |
| Alex Thurman | Option | 6,126 | 48.46 | — |
| Alex Thurman | Option | 4,894 | 85.78 | — |
The executive compensation program is designed to attract and retain top-caliber executives, reward both near-term results and long-term growth, and align pay with performance and shareholder interests. A significant portion of compensation is variable, with 93% of the CEO's and 85% of other NEOs' target compensation tied to performance-based annual bonuses and equity grants.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-28 | 47,653,794 | 4,272,830 | 85,861 | 91.77% | Passed |
| 2025 | 2025-05-29 | 48,971,169 | 1,143,789 | 57,534 | 97.72% | Passed |
| 2024 | 2024-05-30 | 43,205,860 | 1,952,506 | 140,076 | 95.38% | Passed |
| 2023 | 2023-06-01 | 37,101,296 | 3,742,568 | 30,094 | 90.84% | Passed |
| 2022 | 2022-06-02 | 36,804,663 | 2,718,207 | 33,046 | 93.12% | Passed |
| 2021 | 2021-06-03 | 38,105,963 | 2,834,497 | 57,484 | 93.08% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-28 | 91.77%a |
| 2025 | 2025-05-29 | 97.72%b |
| 2024 | 2024-05-30 | 95.38%c |
a. Approved under the standard stated in the filing — “What effect do withhold votes, abstentions and broker non-votes have on the proposals? For Proposal 1 (election of directors), shares voted "WITHHOLD" will not be counted in determining the outcome of a director nominee's election.”.
b. Approved under the standard stated in the filing — “What effect do withhold votes, abstentions and broker non-votes have on the proposals? For Proposal 1 (election of directors), shares voted "WITHHOLD" will not be counted in determining the outcome of a director nominee's election.”.
c. Approved under the standard stated in the filing — “Abstentions with respect to any other proposal at the Annual Meeting will have the same effect as a vote "AGAINST" the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 67.4 : 1 |
|---|---|
| CEO total compensation | $12,033,637 |
| Median employee compensation | $178,462 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark J. FoleyIndependent · Lead Independent Director · Compensation, Nominating and Governance (Chair) | $0 | $329,310 | $160,001 | $0 | $0 | $489,311 |
| David F. HoffmeisterIndependent · Audit (Chair) | 0 | 283,358 | 160,001 | 0 | 0 | 443,359 |
| Marc A. StapleyIndependent · Audit · Compensation, Nominating and Governance | 0 | 280,514 | 160,001 | 0 | 0 | 440,515 |
| Denice M. TorresIndependent · Compensation, Nominating and Governance | 0 | 268,988 | 160,001 | 0 | 0 | 428,989 |
| Leana S. Wen, M.DIndependent · Audit | 0 | 268,988 | 160,001 | 0 | 0 | 428,989 |
| Aimee S. WeisnerIndependent · Audit | 0 | 268,988 | 160,001 | 0 | 0 | 428,989 |
| Gilbert H. Kliman, M.DIndependent · Compensation, Nominating and Governance | 0 | 268,988 | 160,001 | 0 | 0 | 428,989 |
| Thomas W. BurnsEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $360,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 12,500 |
| Stock ownership guideline | $6 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $0 |
| Equity awards (grant-date value) | $1,969,134 |
| All other compensation | $0 |
| Total cost of the board | $1,969,134 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies GLAUKOS Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including GLAUKOS Corp.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | PROCEPT BioRobotics | 2025 | Larry Wood | 304,830 | 7,217,251 | 7,226,599 | 243,864 | 16,783,853 |
| 4 | Exact Sciences | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 5 | Natera | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 6 | BridgeBio Pharmaceuticals | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 7 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 8 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 9 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 10 | Haemonetics | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 11 | GLAUKOS Corp | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 12 | Ultragenyx Pharmaceuticals | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 13 | Vericel | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 14 | iRhythm Technologies | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 15 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 16 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 17 | Intra-Cellular Therapeutics | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 18 | Inspire Medical | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 19 | STAAR Surgical | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 20 | Repligen | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 21 | Inari Medical | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 22 | Lantheus | 2025 | Mary Anne Heino | 100,000 | 749,963 | 749,999 | 0 | 2,173,930 |
| — | Axonics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| GLAUKOS Corp | 177.5% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Axonics | not disclosed | not disclosed | not disclosed | not disclosed |
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharmaceuticals | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Exact Sciences | 47% | PSU 60 · RSU 40 | No | Aon |
| Haemonetics | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Halozyme | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Inari Medical | 118% | RSU 75 · Option 25 | not disclosed | FW Cook |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Inspire Medical | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Intra-Cellular Therapeutics | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| iRhythm Technologies | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| Lantheus | 47% | PSU 50 · RSU 25 · Options 25 | Yes — relative Total Shareholder Return (rTSR) against the S&P 400 Health Care Index | Pearl Meyer |
| Madrigal Pharmaceuticals | 195% | PSU 33 · RSU 33 · Options 33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia |
| Natera | 131.1% | PSU 50 · RSU 50 | No | Aon |
| PROCEPT BioRobotics | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Repligen | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| STAAR Surgical | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Ultragenyx Pharmaceuticals | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vericel | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Thomas Burns | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952 |
| 2 | Section 01, Joseph Gilliam | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 7,785,619. Filing ↗machine: r11 · c38 · span 1948374–1948383 |
| 3 | Section 01, Tomas Navratil | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 3,415,370. Filing ↗machine: r22 · c38 · span 2104168–2104177 |
| 4 | Section 01, Alex Thurman | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023”. As printed: 2,937,431. Filing ↗machine: r17 · c38 · span 2032144–2032153 |
| 5 | Section 03, Joseph Gilliam OTHER | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r11 · c17 · span 1940497–1940506 |
| 6 | Section 03, Thomas Burns OTHER | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r6 · c18 · span 1869064–1869073 |
| 7 | Section 03, Tomas Navratil OTHER | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r22 · c17 · span 2096291–2096300 |
| 8 | Section 07, pay ratio | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “CEO Pay Ratio”. As printed: 67.4 : 1. Filing ↗ |
| 9 | Section 08, Mark J. Foley | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 489,311. Filing ↗machine: span 637926–638173 |
| 10 | Section 08, David F. Hoffmeister | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 443,359. Filing ↗machine: span 645384–645631 |
| 11 | Section 08, Marc A. Stapley | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 440,515. Filing ↗machine: span 660298–660545 |
| 12 | Section 08, Denice M. Torres | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 667752–667999 |
| 13 | Section 08, Leana S. Wen, M.D | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 682678–682925 |
| 14 | Section 08, Aimee S. Weisner | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 675206–675453 |
| 15 | Section 08, Gilbert H. Kliman, M.D | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 428,989. Filing ↗machine: span 652845–653092 |
| 16 | Section 08, Thomas W. Burns | DEF 14A | 2026-04-16 | 0001193125-26-157829 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 02, Alex Thurman 2026-04-30 | Form 4 | 2026-05-04 | 0001920061-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Alex Thurman 2026-04-30 | Form 4 | 2026-05-04 | 0001920061-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Alex Thurman 2026-04-30 | Form 4 | 2026-05-04 | 0001920061-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Leana Wen 2026-05-01 | Form 4 | 2026-05-04 | 0001847598-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Joseph Gilliam 2026-05-01 | Form 4 | 2026-05-04 | 0001705850-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Gilbert H. Kliman 2026-05-11 | Form 4 | 2026-05-13 | 0001293171-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Gilbert H. Kliman 2026-05-11 | Form 4 | 2026-05-13 | 0001293171-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Gilbert H. Kliman 2026-05-11 | Form 4 | 2026-05-13 | 0001293171-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Gilbert H. Kliman 2026-05-14 | Form 4 | 2026-05-18 | 0001293171-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Gilbert H. Kliman 2026-05-14 | Form 4 | 2026-05-18 | 0001293171-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Gilbert H. Kliman 2026-05-14 | Form 4 | 2026-05-18 | 0001293171-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, David F. Hoffmeister 2026-05-26 | Form 4 | 2026-05-28 | 0001305975-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, David F. Hoffmeister 2026-05-26 | Form 4 | 2026-05-28 | 0001305975-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Marc A. Stapley 2026-05-28 | Form 4 | 2026-06-01 | 0001539796-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Gilbert H. Kliman 2026-05-28 | Form 4 | 2026-06-01 | 0001293171-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Gilbert H. Kliman 2026-05-28 | Form 4 | 2026-06-01 | 0001293171-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, David F. Hoffmeister 2026-05-28 | Form 4 | 2026-06-01 | 0001305975-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Mark J. Foley 2026-05-28 | Form 4 | 2026-06-01 | 0001529196-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Mark J. Foley 2026-05-28 | Form 4 | 2026-06-01 | 0001529196-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Denice M. Torres 2026-05-28 | Form 4 | 2026-06-01 | 0001820278-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Denice M. Torres 2026-05-28 | Form 4 | 2026-06-01 | 0001820278-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Aimee S. Weisner 2026-05-28 | Form 4 | 2026-06-01 | 0001227308-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Aimee S. Weisner 2026-05-28 | Form 4 | 2026-06-01 | 0001227308-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Leana Wen 2026-05-28 | Form 4 | 2026-06-01 | 0001847598-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Denice M. Torres 2026-05-28 | Form 4 | 2026-06-23 | 0001820278-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, David F. Hoffmeister 2026-05-28 | Form 4 | 2026-06-23 | 0001305975-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Gilbert H. Kliman 2026-05-28 | Form 4 | 2026-06-23 | 0001293171-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Aimee S. Weisner 2026-05-28 | Form 4 | 2026-06-23 | 0001227308-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Marc A. Stapley 2026-05-28 | Form 4 | 2026-06-23 | 0001539796-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Leana Wen 2026-05-28 | Form 4 | 2026-06-23 | 0001847598-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Mark J. Foley 2026-05-28 | Form 4 | 2026-06-23 | 0001529196-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Leana Wen 2026-05-28 | Form 4 | 2026-06-01 | 0001847598-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, David F. Hoffmeister 2026-05-28 | Form 4 | 2026-06-01 | 0001305975-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Marc A. Stapley 2026-05-28 | Form 4 | 2026-06-01 | 0001539796-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Tomas Navratil 2026-06-16 | Form 4 | 2026-06-18 | 0001920053-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Tomas Navratil 2026-06-25 | Form 4 | 2026-06-29 | 0001920053-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Joseph Gilliam 2026-06-25 | Form 4 | 2026-06-29 | 0001705850-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Thomas William Burns 2026-06-25 | Form 4 | 2026-06-29 | 0001644557-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Tomas Navratil 2026-07-01 | Form 4 | 2026-07-08 | 0001920053-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Alex Thurman 2026-07-06 | Form 4 | 2026-07-08 | 0001920061-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Alex Thurman 2026-07-06 | Form 4 | 2026-07-08 | 0001920061-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Alex Thurman 2026-07-06 | Form 4 | 2026-07-08 | 0001920061-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Alex Thurman 2026-07-09 | Form 4 | 2026-07-13 | 0001920061-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Alex Thurman 2026-07-09 | Form 4 | 2026-07-13 | 0001920061-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Alex Thurman 2026-07-09 | Form 4 | 2026-07-13 | 0001920061-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Alex Thurman 2026-07-16 | Form 4 | 2026-07-21 | 0001920061-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Alex Thurman 2026-07-16 | Form 4 | 2026-07-21 | 0001920061-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Alex Thurman 2026-07-16 | Form 4 | 2026-07-21 | 0001920061-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Leana Wen 2026-07-31 | Form 4 | 2026-08-03 | 0001847598-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Alex Thurman 2026-08-07 | Form 4 | 2026-08-11 | 0001920061-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Alex Thurman 2026-08-07 | Form 4 | 2026-08-11 | 0001920061-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Alex Thurman 2026-08-07 | Form 4 | 2026-08-11 | 0001920061-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Joseph Gilliam 2026-08-11 | Form 4 | 2026-08-13 | 0001705850-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Gilbert H. Kliman 2026-08-19 | Form 4 | 2026-08-20 | 0001293171-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Gilbert H. Kliman 2026-08-19 | Form 4 | 2026-08-20 | 0001293171-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Gilbert H. Kliman 2026-08-19 | Form 4 | 2026-08-20 | 0001293171-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Tomas Navratil 2026-08-28 | Form 4 | 2026-09-01 | 0001920053-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Tomas Navratil 2026-08-28 | Form 4 | 2026-09-01 | 0001920053-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Tomas Navratil 2026-08-28 | Form 4 | 2026-09-01 | 0001920053-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Tomas Navratil 2026-09-16 | Form 4 | 2026-09-18 | 0001920053-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Tomas Navratil 2026-09-25 | Form 4 | 2026-09-28 | 0001920053-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Tomas Navratil 2026-09-25 | Form 4 | 2026-09-28 | 0001920053-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Tomas Navratil 2026-09-25 | Form 4 | 2026-09-28 | 0001920053-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Tomas Navratil 2026-09-25 | Form 4 | 2026-09-28 | 0001920053-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Tomas Navratil 2026-10-05 | Form 4 | 2026-10-07 | 0001193125-26-417151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Tomas Navratil 2026-10-05 | Form 4 | 2026-10-07 | 0001193125-26-417151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Tomas Navratil 2026-10-05 | Form 4 | 2026-10-07 | 0001193125-26-417151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0001193125-26-255758 | Item 5.07 · say-on-pay result. As reported: 91.77% (votes for as printed: 47,653,794). Filing ↗ |
| 100 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0001558370-25-008365 | Item 5.07 · say-on-pay result. As reported: 97.72% (votes for as printed: 48,971,169). Filing ↗ |
| 101 | Section 06, 2024 vote | Form 8-K | 2024-06-05 | 0001558370-24-008913 | Item 5.07 · say-on-pay result. As reported: 95.38% (votes for as printed: 43,205,860). Filing ↗ |
| 102 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 103 | Section 09b board cost (computed) | Computed | — | — | Cash 0 + equity 1,969,134 + all other 0 = 1,969,134, summed across the director compensation table rows.machine: formula: Σ = 1,969,134 |
| 104 | Halozyme, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 105 | Madrigal Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001308179-26-000352 | CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952 |
| 106 | PROCEPT BioRobotics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001588978-26-000017 | CEO total compensation as printed in PROCEPT BioRobotics's own proxy. As printed: 16,783,853. Filing ↗machine: r2 · c48 · span 520911–520921 |
| 107 | Exact Sciences, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 108 | Natera, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 109 | BridgeBio Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharmaceuticals's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 110 | Insmed, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 111 | Blueprint Medicines, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 112 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 113 | Haemonetics, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 114 | GLAUKOS Corp (subject), Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in GLAUKOS Corp's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952 |
| 115 | Ultragenyx Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceuticals's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 116 | Vericel, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 117 | iRhythm Technologies, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 118 | Apellis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 119 | TransMedics Group, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150357 | CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179 |
| 120 | Intra-Cellular Therapeutics, Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapeutics's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 121 | Inspire Medical, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical's own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 122 | STAAR Surgical, Section 10b CEO total | DEF 14A | 2026-05-04 | 0000718937-26-000015 | CEO total compensation as printed in STAAR Surgical's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486 |
| 123 | Repligen, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 124 | Inari Medical, Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical's own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 125 | Lantheus, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001193125-26-117649 | CEO total compensation as printed in Lantheus's own proxy. As printed: 2,173,930. Filing ↗machine: r3 · c39 · span 957618–957628 |
| 126 | Section 10a, Halozyme reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 127 | Section 10a, iRhythm Technologies reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 128 | Section 10a, Natera reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 129 | Section 10a, Repligen reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 130 | Section 10a, Vericel reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 131 | Section 10a, STAAR Surgical reciprocity | DEF 14A | — | 0000718937-26-000015 | STAAR Surgical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 132 | Section 10a, Intra-Cellular Therapeutics reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapeutics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 133 | Section 10a, Inari Medical reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 134 | Section 10a, Inspire Medical reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 135 | Section 10a, Haemonetics reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 136 | Section 10a, Blueprint Medicines reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 137 | Section 10a, Insmed reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 138 | Section 10a, Ultragenyx Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 139 | Section 10a, Exact Sciences reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 140 | Section 10a, PROCEPT BioRobotics reciprocity | DEF 14A | — | 0001588978-26-000017 | PROCEPT BioRobotics's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 141 | Section 10a, Apellis Pharmaceuticals reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 142 | Section 10a, BridgeBio Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 143 | Section 10a, TransMedics Group reciprocity | DEF 14A | — | 0001193125-26-150357 | TransMedics Group names GLAUKOS Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 144 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
| 145 | Section 10a, Madrigal Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000352 | Madrigal Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GLAUKOS Corp. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the GLAUKOS Corp Executive Compensation Report
$1,500